Aldolase Test Explained: Normal Range, High Levels, Muscle Damage & Report Reading (India 2026) | एल्डोलेज टेस्ट गाइड
Aldolase Test Explained: Normal Range, High Levels, Muscle Damage & Report Reading (India 2026)
एल्डोलेज टेस्ट गाइड: Normal Range, High Aldolase के Causes, Muscle vs Liver vs Neurological Disease, CPK के साथ Comparison — पूरी जानकारी
Your rheumatologist has ordered a "serum aldolase" test alongside CK (creatine kinase) and inflammatory markers as part of a muscle disease workup. Or your report shows "Aldolase: 12.8 U/L" and you want to understand whether this is concerning, what it means for your diagnosis, and how it differs from the more commonly ordered CPK/CK muscle enzyme test. The Aldolase Test measures the level of the enzyme aldolase in the blood. Aldolase is a glycolytic enzyme — present in high concentrations inside muscle cells, red blood cells, and liver cells — and its appearance in the bloodstream at elevated levels indicates cellular damage or death releasing intracellular enzyme into the circulation. While CPK (creatine kinase) remains the primary muscle enzyme marker in most clinical panels, aldolase provides complementary and sometimes unique diagnostic information — particularly in inflammatory muscle diseases (polymyositis, dermatomyositis), muscular dystrophies, and situations where CPK may be normal despite active muscle disease. In India, where inflammatory myopathies are increasingly recognised and where autoimmune muscle disease investigation is becoming more sophisticated at rheumatology centres, understanding the aldolase test is increasingly clinically relevant.
For related muscle enzyme tests, see our CPK / CPK-MB guide. For inflammatory markers, see our hs-CRP guide. For reading lab reports generally, see our beginner's guide.
Rheumatologist ने CK और inflammatory markers के साथ "serum aldolase" order किया। या report में "Aldolase: 12.8 U/L" है — concerning है? Diagnosis के लिए क्या मतलब? CPK से कैसे different? Aldolase Test = blood में aldolase enzyme का level measure करता है। Aldolase = glycolytic enzyme, muscle cells + red blood cells + liver cells में high concentration। Blood में elevated = cellular damage/death → intracellular enzyme circulation में release। CPK primary muscle marker रहती है — aldolase complementary और sometimes unique information: inflammatory muscle diseases (polymyositis, dermatomyositis), muscular dystrophies, CPK normal despite active muscle disease में। यह guide सब explain करती है।Table of Contents / विषय सूची
- What Is Aldolase? / Aldolase क्या है?
- Why Is the Aldolase Test Ordered?
- Normal Range / नॉर्मल रेंज
- High Aldolase — Causes & Clinical Significance
- Aldolase vs CPK — When Each Is More Useful
- Muscle Disease vs Nerve Disease — Using Aldolase
- Aldolase in Inflammatory Myopathy — India Context
- Test Preparation / टेस्ट की तैयारी
- Frequently Asked Questions / अक्सर पूछे जाने वाले सवाल
What Is Aldolase?
Aldolase (formally fructose-1,6-bisphosphate aldolase, EC 4.1.2.13) is a ubiquitous glycolytic enzyme that catalyses the reversible cleavage of fructose-1,6-bisphosphate (FBP) into dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-phosphate (G3P) — step 4 in the ten-step glycolytic pathway. There are three genetically distinct aldolase isoenzymes in humans: Aldolase A (ALDOA) — predominant in skeletal muscle and red blood cells; Aldolase B (ALDOB) — predominant in the liver, kidney, and small intestine; and Aldolase C (ALDOC) — predominant in the brain and neurons. The standard serum aldolase test measures total aldolase activity — the combined contribution of all isoenzymes present in the blood.
Aldolase (fructose-1,6-bisphosphate aldolase, EC 4.1.2.13) = ubiquitous glycolytic enzyme। Fructose-1,6-bisphosphate → DHAP + G3P catalyse करता है (glycolytic pathway का step 4)। Three isoenzymes: Aldolase A (ALDOA) — skeletal muscle + red blood cells predominant। Aldolase B (ALDOB) — liver, kidney, small intestine। Aldolase C (ALDOC) — brain, neurons। Standard serum aldolase test = total aldolase activity (all isoenzymes combined)।- Normal (low) serum aldolase: Intact cell membranes contain aldolase within the cytoplasm. Normal cell turnover releases tiny amounts of aldolase into the bloodstream — producing the low baseline serum level. The half-life of aldolase in circulation is approximately 12 hours — shorter than CPK's half-life of approximately 24–48 hours.
- Elevated serum aldolase — the mechanism: When muscle cells sustain damage from any cause — inflammatory infiltration (myositis), hypoxia (ischaemia), toxins (statin myopathy, alcohol), mechanical trauma (rhabdomyolysis), or genetic structural abnormality (muscular dystrophy) — the muscle cell membrane is disrupted. This allows the intracellular contents (including large enzyme molecules like aldolase, CK, LDH, and AST) to leak across the damaged membrane into the interstitial fluid, then into lymphatics, and then into the bloodstream. The rate of rise depends on the severity and rapidity of muscle damage. The rate of decline after the damaging insult has stopped reflects the combined effects of enzyme clearance from the blood and cessation of leakage.
- Aldolase isoforms — why liver disease can also raise serum aldolase: Hepatocytes (liver cells) contain significant amounts of Aldolase B. Acute liver damage (hepatitis, liver ischaemia, paracetamol toxicity) releases hepatic Aldolase B into the bloodstream — raising serum total aldolase. This means elevated aldolase is not exclusive to muscle disease. The pattern of other enzymes (ALT/SGPT, AST/SGOT, ALP, CK) helps distinguish the source.
Why Is the Aldolase Test Ordered?
The most common clinical indication for serum aldolase in Indian rheumatology practice. Polymyositis (PM) and dermatomyositis (DM) are autoimmune inflammatory muscle diseases causing: proximal muscle weakness (difficulty rising from a chair, climbing stairs, lifting arms above head), muscle pain and tenderness, elevated muscle enzymes, and characteristic skin changes in DM (heliotrope rash around the eyes, Gottron's papules over knuckles). Aldolase is ordered as part of the myositis enzyme panel — alongside CK, LDH, ALT (SGPT), and AST (SGOT) — to: (a) confirm active muscle cell damage; (b) monitor treatment response (aldolase typically falls with effective immunosuppression); (c) detect disease reactivation during tapering of immunosuppressive therapy. Important: approximately 10–15% of PM/DM patients have elevated aldolase with only minimally elevated or normal CK — in these patients, aldolase may be the more sensitive marker of residual disease activity.
Most common Indian rheumatology indication। Polymyositis (PM) + dermatomyositis (DM): proximal muscle weakness (chair से rise, stairs, arms above head difficult), muscle pain, elevated muscle enzymes, skin changes (DM में heliotrope rash, Gottron's papules)। Aldolase ordered: myositis enzyme panel में (CK + LDH + ALT/SGPT + AST/SGOT)। Uses: (a) active muscle cell damage confirm। (b) treatment response monitor (immunosuppression → aldolase fall)। (c) disease reactivation detect (tapering)। 10–15% PM/DM: elevated aldolase + normal/minimal CK → aldolase more sensitive।The muscular dystrophies are a group of inherited genetic diseases causing progressive skeletal muscle weakness and degeneration. In India, Duchenne Muscular Dystrophy (DMD — the most severe form, affecting boys, due to dystrophin gene mutations on the X chromosome), Becker Muscular Dystrophy (BMD — milder than DMD), and Limb-Girdle Muscular Dystrophies (LGMD — affecting pelvic and shoulder girdle muscles) are the most commonly encountered. All muscular dystrophies produce markedly elevated CK — often 10–100× the upper limit of normal — because the defective structural proteins (dystrophin in DMD/BMD, various proteins in LGMD) cause ongoing muscle cell membrane fragility and enzyme leakage. Aldolase is also markedly elevated in active muscular dystrophies. While CK is the primary screening marker for muscular dystrophy (due to its greater sensitivity), aldolase may be ordered to: confirm elevated muscle enzymes in a patient with a known or suspected dystrophy; monitor disease progression; and occasionally when CK values seem discordant with clinical severity. In India, genetic confirmation of DMD/BMD requires molecular genetic testing (MLPA for large deletions, sequencing for point mutations) — aldolase and CK are screening markers, not diagnostic markers.
Muscular dystrophies: inherited genetic diseases। India में: Duchenne MD (DMD — boys, dystrophin gene mutations, most severe), Becker MD (BMD — milder), Limb-Girdle MD (LGMD — pelvic + shoulder girdle)। All: markedly elevated CK (10–100× ULN — defective structural proteins → membrane fragility → enzyme leakage)। Aldolase: markedly elevated in active dystrophies। CK = primary screening marker (greater sensitivity)। Aldolase: confirm elevated muscle enzymes, disease progression monitor, CK discordant with clinical severity। India में: genetic confirmation MLPA + sequencing — aldolase + CK = screening markers।A fundamental clinical question when a patient presents with muscle weakness is whether the weakness is myopathic (primary muscle problem — the muscle cells themselves are damaged) or neurogenic (secondary to nerve damage — the muscles are structurally normal but denervated). This distinction has fundamentally different diagnostic and therapeutic implications. Serum aldolase and CK: in myopathic conditions (PM/DM, muscular dystrophy, metabolic myopathy), both aldolase and CK are elevated — because muscle cells are actively damaged and leaking enzymes. In purely neurogenic conditions (motor neuron disease — ALS, spinal muscular atrophy; peripheral neuropathies; radiculopathy), the muscle cells are structurally preserved (not primarily damaged) — aldolase and CK are typically normal or only very mildly elevated (from disuse atrophy of the denervated muscle). This is an important principle used in the electromyography (EMG) + nerve conduction + enzyme panel approach to evaluating muscle weakness in Indian neurology practice. Note: very severe and longstanding neurogenic weakness can eventually lead to muscle atrophy with secondary myopathic changes and mild enzyme elevation — but the primary distinction in early disease is preserved muscle enzymes in neurogenic disease.
Fundamental question: muscle weakness = myopathic (primary muscle problem, cells damaged) या neurogenic (nerve damage, muscles structurally normal but denervated)?। Myopathic (PM/DM, muscular dystrophy, metabolic myopathy): aldolase + CK both elevated (muscle cells actively damaged)। Neurogenic (ALS, SMA, peripheral neuropathy, radiculopathy): muscle cells structurally preserved → aldolase + CK typically normal या very mildly elevated (disuse atrophy only)। EMG + nerve conduction + enzyme panel approach in Indian neurology। Very severe longstanding neurogenic weakness → eventually myopathic changes + mild elevation — early disease में primary distinction: neurogenic = preserved muscle enzymes।Less common but clinically important indications for aldolase:
- Rhabdomyolysis: Massive acute muscle breakdown from trauma, crush injury, prolonged seizure, extreme exertion (marathon runners, military training, extreme heat), toxins (statin myopathy, cocaine, heroin), or hyperthermia. Both CK and aldolase are dramatically elevated — CK typically to tens of thousands U/L, aldolase proportionally elevated. Rhabdomyolysis is a medical emergency due to myoglobinuria-induced acute kidney injury.
- Viral myositis: Influenza, dengue, COVID-19, and other viruses can cause transient skeletal muscle inflammation with elevated CK and aldolase. Usually self-limiting.
- Statin myopathy: Statins (atorvastatin, rosuvastatin, simvastatin — widely used in India for cardiovascular risk reduction) can cause muscle injury ranging from benign myalgias (muscle pain, normal enzymes) to myositis (muscle pain + elevated enzymes) to life-threatening rhabdomyolysis.
- Haemolytic anaemia: Red blood cells contain Aldolase A — haemolysis (destruction of red blood cells) releases aldolase into the bloodstream. In severe haemolytic anaemia, aldolase may be mildly elevated from RBC destruction rather than from muscle damage.
- Hepatitis and liver disease: Acute viral hepatitis (HBV, HCV, hepatitis A), alcoholic hepatitis, and toxic hepatitis can elevate aldolase from hepatic Aldolase B release — typically with concomitant ALT/AST elevation disproportionate to any CK elevation.
Normal Range / नॉर्मल रेंज
*Reference ranges for aldolase vary between assay methods and laboratories. The values below represent the most widely used reference ranges in Indian NABL-accredited labs using colorimetric or spectrophotometric assay methods. Always use the reference range on your specific lab report. Units: U/L (units per litre). Some labs may report in nmol/s/L (SI units) — conversion: 1 U/L ≈ 16.67 nmol/s/L.
| Group | Normal Range (U/L) | Clinical Notes |
|---|---|---|
| Adult (male) | 1.0–7.5 U/L | Men have slightly higher muscle mass and higher baseline aldolase. Values above 7.5 U/L in an adult man warrant clinical evaluation if unexplained — though mild elevations (7.5–10 U/L) are sometimes seen from strenuous physical activity or intramuscular injections. |
| Adult (female) | 1.0–6.5 U/L | Women have slightly lower aldolase due to lower average muscle mass. Pregnancy may slightly alter enzyme levels. Values above 6.5 U/L warrant evaluation in the clinical context. |
| Children (neonates) | Up to 14.5 U/L | Newborns have physiologically higher aldolase — reflecting high foetal muscle activity and metabolic turnover. Aldolase gradually decreases through infancy and childhood to adult levels by adolescence. |
| Children (2–16 years) | 3.4–11.8 U/L | Children have higher aldolase than adults, reflecting greater muscle growth and turnover. Muscular dystrophies presenting in childhood (DMD — typically ages 2–5) will show dramatically elevated values (often 10–50× ULN) against these paediatric ranges. |
| Elderly (above 65) | 0.8–5.5 U/L | Sarcopenia (age-related muscle mass reduction) causes progressive decline in baseline aldolase with advancing age. Elderly patients have lower baseline aldolase — even values slightly above the adult reference range may be relatively more significant in this group. |
- Strenuous physical exercise: Heavy weightlifting, marathon running, high-intensity interval training (HIIT), and other forms of intense physical exertion temporarily damage muscle fibres — causing a transient rise in both CK and aldolase that peaks 24–72 hours after exercise and returns to baseline over 5–7 days. A person who trained intensely 24–48 hours before an aldolase test may have a mildly elevated result that is physiological, not pathological. Always inform the requesting physician of recent heavy exercise. If a high result is obtained and muscle disease is not suspected, repeat the test after 7 days of rest.
- Intramuscular (IM) injections: Injections into the gluteal or deltoid muscle (very common in India — antibiotics, anti-inflammatory injections, B12 injections, vaccine administration, iron injections) can cause local muscle cell damage at the injection site, releasing CK and aldolase. Multiple IM injections before aldolase testing can produce mildly elevated values. Note all IM injections given within 2 weeks of testing.
- Haemolysis in the blood sample (in-vitro haemolysis): If the blood sample is improperly collected (excessive venipuncture trauma, delayed processing, temperature extremes) or transported without proper care, red blood cells may lyse within the tube. Since RBCs contain Aldolase A, in-vitro haemolysis releases RBC aldolase into the serum — producing a falsely elevated aldolase result without any in-vivo muscle or liver disease. A haemolysed sample should always be repeated. Labs should reject haemolysed samples for aldolase.
- Recent crush injury, falls, or trauma: Any traumatic event causing muscle bruising, contusion, or crush injury (even a minor fall) will transiently elevate aldolase and CK from local muscle damage at the injury site.
High Aldolase — Causes & Clinical Significance
The degree of aldolase elevation provides clinically useful information about the likely severity and cause of muscle or organ damage:
Aldolase elevation की degree = severity और cause के बारे में clinically useful information।| Elevation Level | Approximate Value | Likely Causes |
|---|---|---|
| Mild (1–2× ULN) | ~7.5–15 U/L (adults) | Recent strenuous exercise, IM injections, mild viral myositis, early or low-grade inflammatory myopathy, stable muscular dystrophy, mild alcohol-related myopathy, early statin myopathy, haemolysis (in-vitro or mild haemolytic anaemia). |
| Moderate (2–5× ULN) | ~15–37 U/L (adults) | Active polymyositis or dermatomyositis, moderately active muscular dystrophy, significant viral myositis (influenza, dengue), significant hepatitis (ALT/AST also elevated), significant statin myopathy, acute trauma with significant muscle bruising. |
| High (5–10× ULN) | ~37–75 U/L (adults) | Severe active inflammatory myopathy (untreated PM/DM at presentation), active Duchenne or Becker MD, significant rhabdomyolysis (though CK typically more dramatically elevated), severe acute hepatitis. |
| Very High (>10× ULN) | >75 U/L (adults) | Rhabdomyolysis (with very high CK), advanced Duchenne MD in active phase, severe acute hepatic necrosis (fulminant hepatitis), malignant hyperthermia, neuroleptic malignant syndrome. |
Aldolase vs CPK — When Each Is More Useful
- Inflammatory myopathy with normal or mildly elevated CK: In approximately 10–15% of polymyositis and dermatomyositis patients, CK is only mildly elevated or within the normal range at presentation — but aldolase remains elevated, reflecting ongoing muscle inflammation. This is particularly documented in anti-synthetase syndrome, anti-MDA5-associated dermatomyositis, and some cases of inclusion body myositis (IBM). Aldolase may detect active disease when CK alone would falsely reassure.
- Monitoring myositis treatment response: In established PM/DM on immunosuppressive therapy (prednisolone, methotrexate, azathioprine, mycophenolate, rituximab), both CK and aldolase are monitored. Some patients have clinical improvement with falling aldolase but persistent mild CK elevation (or vice versa). Using both markers gives a more complete picture of treatment response than either alone.
- Hereditary fructose intolerance and metabolic myopathies: Certain glycogen storage diseases affecting muscle (Pompe disease, McArdle disease) and rare metabolic myopathies can produce elevated aldolase as a byproduct of glycolytic pathway dysfunction. CPK is also elevated but aldolase may provide additional metabolic pathway information in specialist evaluation.
- Haemolytic conditions causing RBC enzyme release: When haemolysis is the predominant process (not muscle damage), aldolase may be elevated from RBC Aldolase A while CK is normal or only mildly elevated — helping to distinguish haemolytic from myopathic enzyme release in ambiguous presentations.
- Acute myocardial infarction (heart attack): CPK-MB (the cardiac-specific isoform of CK) and cardiac troponin are the primary biomarkers for acute MI. Aldolase is not useful for cardiac diagnosis — it rises non-specifically with any large muscle mass injury and has no cardiac-specific isoform available in routine clinical practice.
- Rhabdomyolysis monitoring: In acute rhabdomyolysis, CK rises proportionally much higher than aldolase and is the marker used to assess severity, guide fluid therapy, and monitor resolution. The CK level also determines the risk of acute kidney injury — CK above 5,000 U/L is associated with AKI risk, and CK above 15,000–20,000 U/L usually warrants IV fluid therapy and close monitoring.
- Muscular dystrophy screening in children: CK is dramatically more sensitive than aldolase for detecting DMD — CK values of 50–200× the upper limit of normal are characteristic, while aldolase is typically elevated to a lesser degree. CK is the primary enzyme marker for DMD screening.
- Statin myopathy monitoring: Standard guidelines for statin myopathy monitoring use CK as the benchmark — a CK above 5× ULN with symptoms indicates statin myositis requiring dose reduction or discontinuation; above 10× ULN = discontinue statin; above 10,000 U/L = rhabdomyolysis requiring hospitalisation.
- Isoform analysis: CPK has clinically useful isoforms (MM, MB, BB) that help localise the source of enzyme release to skeletal muscle, cardiac muscle, or brain. Aldolase isoform testing is not routinely available or clinically used in Indian labs.
Muscle Disease vs Nerve Disease — Using Aldolase
- Step 1 — Is aldolase elevated AND is CK also elevated? Both elevated → myopathic process most likely. Proceed to further myopathy workup: age of onset, pattern of weakness (proximal vs distal, symmetric vs asymmetric), family history, skin changes, drug history. Both normal → neurogenic process more likely — refer for EMG/NCS.
- Step 2 — If aldolase elevated but CK is normal: Consider: (a) early or low-grade inflammatory myopathy — full myositis panel (anti-Jo-1, anti-MDA5, anti-Mi-2, anti-SRP, anti-HMGCR antibodies); (b) haemolytic process — check LDH, bilirubin, reticulocyte count; (c) liver disease — check ALT, AST, ALP; (d) in-vitro haemolysis of sample — repeat with careful sample handling; (e) recent strenuous exercise or IM injections — repeat after 7 days rest.
- Step 3 — Pattern of associated enzyme elevations helps localise: Aldolase elevated + CK dramatically elevated + minimal ALT/AST rise → skeletal muscle predominant source. Aldolase elevated + CK mildly elevated + ALT/AST significantly elevated → liver disease contributing. Aldolase elevated + CK elevated + LDH elevated + dark urine → rhabdomyolysis with myoglobinuria → URGENT medical evaluation.
- Step 4 — Contextualise the aldolase value with the clinical picture: An aldolase of 12 U/L in an otherwise healthy person who ran a marathon yesterday is physiological. The same value in a 45-year-old woman with 3 months of progressive proximal muscle weakness and elevated inflammatory markers is clinically significant. Never interpret aldolase in isolation.
Aldolase in Inflammatory Myopathy — India Context
Inflammatory myopathies (IM) — polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM), and immune-mediated necrotising myopathy (IMNM) — are autoimmune diseases increasingly recognised in Indian rheumatology practice. Key features for Indian clinicians and patients:
- Proximal muscle weakness: The characteristic symptom — difficulty rising from a squat (sitting on the floor — extremely common daily activity in India), climbing stairs, lifting overhead, or combing hair. This proximal distribution distinguishes inflammatory myopathy from distal neuropathy.
- Muscle enzyme elevation: CK is elevated in 70–90% of PM/DM patients (often 5–50× ULN); aldolase is elevated in 85–95% of active PM/DM. LDH, ALT, and AST may also be elevated (from muscle cell damage releasing these enzymes — a pattern sometimes confused with primary liver disease).
- Skin changes (DM specific): Heliotrope rash (purple-blue discolouration around the eyes), Gottron's papules (red/purple papules over finger knuckles), V-sign rash (sun-exposed chest and neck), shawl sign (shoulders and upper back), and mechanic's hands (cracked, hyperkeratotic skin on lateral fingers). These skin findings can precede or accompany muscle weakness.
- Association with malignancy (paraneoplastic myopathy): DM in adults above 45 years has a significantly elevated risk of underlying malignancy — particularly cervical, ovarian, lung, breast, and colon cancer. All newly diagnosed adult DM patients should have age-appropriate cancer screening (including CT chest/abdomen/pelvis in India, mammography in women, CEA, CA-125, PSA as appropriate). PM and IBM have a lower but still elevated malignancy association.
- Interstitial lung disease (ILD): A significant proportion of PM/DM patients (particularly those with anti-Jo-1 or anti-MDA5 antibodies) develop interstitial lung disease — a potentially life-threatening complication. Anti-MDA5-associated DM in particular has a high risk of rapidly progressive ILD. All myositis patients should have baseline HRCT chest and pulmonary function tests.
In established PM/DM treated with immunosuppressive therapy, serial aldolase monitoring (alongside CK, LDH, and clinical strength assessment) is a routine component of follow-up at Indian rheumatology centres:
- Treatment-induced enzyme normalisation: Effective immunosuppressive therapy (prednisolone, methotrexate, azathioprine, mycophenolate mofetil) should normalise or significantly reduce both CK and aldolase within 4–12 weeks of starting treatment in most patients. Persistence of elevated aldolase despite treatment suggests insufficient immunosuppression, treatment resistance, or drug-resistant disease (particularly in IMNM associated with anti-HMGCR or anti-SRP antibodies — these may require intravenous immunoglobulin or rituximab).
- Steroid-induced myopathy: High-dose corticosteroids (commonly used for inflammatory myopathy treatment) can themselves cause steroid myopathy — characterised by proximal muscle weakness (predominantly quadriceps), preserved or improving serum CK and aldolase (steroids suppress enzyme leakage while causing mitochondrial dysfunction), and a distinct EMG pattern. This creates a diagnostic challenge: increasing weakness on steroid therapy may represent either inadequate treatment of PM/DM or steroid myopathy. Enzyme trends (CK and aldolase) are critical — worsening disease shows enzyme rise; steroid myopathy shows enzyme stability or fall despite weakness worsening.
- Frequency of monitoring: Monthly during active treatment or dose adjustment; every 3 months once stable; at least every 6 months during maintenance immunosuppression. Aldolase and CK together at each visit.
- Relapse detection: A rising aldolase during steroid tapering (before clinical weakness becomes apparent) can provide early warning of relapse — allowing immunosuppression to be adjusted proactively before clinical deterioration.
Test Preparation Checklist / टेस्ट की तैयारी
-
Avoid strenuous physical exercise for at least 5–7 days before the aldolase test. Heavy exercise causes transient muscle micro-damage that elevates aldolase (and CK) for up to 5–7 days post-exercise. Light walking or normal daily activities are acceptable, but weightlifting, marathon or long-distance running, high-intensity sports, and heavy manual labour should be avoided in the week before testing. Inform the requesting physician of any recent vigorous physical activity if it cannot be avoided before testing.
Strenuous physical exercise: test से कम से कम 5–7 days पहले avoid। Heavy exercise → transient muscle micro-damage → aldolase + CK elevate (5–7 days post-exercise)। Light walking/normal daily activities = acceptable। Weightlifting, marathon, HIIT, heavy manual labour = 1 week पहले avoid। Recent vigorous activity cannot avoid → physician inform। -
Avoid intramuscular (IM) injections for at least 5–7 days before the test. IM injections (into gluteal, deltoid, or quadriceps muscle) cause local muscle trauma that releases CK and aldolase from the injection site. In India, IM injections are extremely common in clinical settings (iron, B12, antibiotics, anti-inflammatory drugs, vaccines). Inform your doctor if IM injections were given recently and note the injection date on the test request form. If possible, schedule the aldolase test before any planned IM injections.
IM injections: test से 5–7 days पहले avoid। IM injections (gluteal, deltoid, quadriceps) → local muscle trauma → CK + aldolase release। India में IM injections very common (iron, B12, antibiotics, anti-inflammatory, vaccines)। Recent IM injections → doctor inform + request form पर injection date note। Planned IM injections हैं → aldolase test पहले schedule। -
Fasting is not required for the aldolase test. Aldolase levels are not significantly affected by food intake. The blood sample can be collected at any time of day. However, since aldolase is often ordered as part of a broader panel that may include fasting tests (fasting glucose, lipid profile), follow your physician's specific instructions for the complete panel.
Aldolase test के लिए fasting required नहीं। Aldolase levels food से significantly affect नहीं। Blood sample anytime। Broader panel (fasting glucose, lipid profile) के साथ → physician के specific instructions follow। -
Inform the doctor and lab about all current medications — particularly statins, corticosteroids, colchicine, hydroxychloroquine, and alcohol consumption. Statins can cause myopathy with elevated aldolase and CK — the test result in a patient on statins must be interpreted with this in mind. Corticosteroids can suppress CK and aldolase in active myositis (potentially masking disease activity). Colchicine (used for gout in India) causes a myoneuropathy with elevated CK. Alcohol causes alcoholic myopathy. All of these context factors are essential for correct interpretation.
Medications inform: Statins (atorvastatin, rosuvastatin — myopathy → elevated aldolase + CK)। Corticosteroids (active myositis में CK + aldolase suppress → disease activity mask)। Colchicine (gout — myoneuropathy, elevated CK)। Alcohol (alcoholic myopathy)। Correct interpretation के लिए all context factors essential। -
Always order aldolase alongside CK (and ideally LDH, ALT, AST) in the same blood draw for the most interpretable panel. An aldolase result without simultaneous CK is difficult to contextualise — the pattern of aldolase relative to CK (and relative to liver enzymes ALT/AST) provides the most clinically useful information. Most myositis evaluation protocols include all five: CK, aldolase, LDH, ALT (SGPT), AST (SGOT) — collected from the same blood draw. Ensure the request form includes all relevant enzymes.
Aldolase: CK + LDH + ALT + AST same blood draw में order करें। Aldolase without CK = contextualise difficult। Pattern (aldolase relative to CK, ALT/AST) = most clinically useful। Myositis evaluation protocol: CK + aldolase + LDH + ALT (SGPT) + AST (SGOT) — same draw। Request form पर सब include। -
Ensure the blood sample is collected carefully and transported promptly to avoid in-vitro haemolysis. Haemolysis (red blood cell rupture within the blood tube) releases RBC Aldolase A into the serum — producing a falsely elevated aldolase result. Ensure the phlebotomist uses correct technique (no prolonged tourniquet, gentle aspiration, correct tube mixing), the sample is not shaken aggressively, and is transported to the lab within 2 hours at room temperature. A haemolysed sample should be rejected and a fresh sample collected.
Sample collection carefully: in-vitro haemolysis avoid। Haemolysis → RBC Aldolase A release → falsely elevated aldolase। Phlebotomist: correct technique (prolonged tourniquet नहीं, gentle aspiration, correct tube mixing)। Sample not aggressively shake। 2 hours के अंदर room temperature पर lab transport। Haemolysed sample = reject + fresh sample collect।
✅ Book Aldolase Test — NABL Labs
For myositis evaluation or muscle disease workup, book Aldolase Test. Avoid strenuous exercise and IM injections for 5–7 days before. No fasting required. Inform lab of medications (especially statins and steroids):
Affiliate link: I may earn a small commission at no extra cost to you. Aldolase testing is available at government hospitals and NABL-accredited pathology labs. Always have results interpreted by a qualified rheumatologist or neurologist alongside clinical history (pattern of weakness, skin changes, drug history), EMG/nerve conduction studies, inflammatory markers, myositis-specific antibody panel, and muscle MRI or biopsy where indicated. Never start or stop immunosuppressive medications based on enzyme results alone.
Aldolase + CK + LDH + ALT + AST complete muscle enzyme panel। Fasting नहीं। 5–7 days पहले exercise + IM injections avoid। Medications inform। NABL lab। Rheumatologist/neurologist से clinical history + EMG + myositis antibody panel + muscle MRI/biopsy के साथ interpret। Immunosuppressives enzyme results alone पर start/stop नहीं।Muscle Health Support & Pain Relief
Two products relevant to muscle health and pain management in the context of muscle enzyme testing — a magnesium glycinate supplement (magnesium plays a critical co-factor role in over 300 enzymatic reactions including the glycolytic pathway in which aldolase participates; magnesium deficiency is extremely common in India and is associated with muscle cramps, weakness, and elevated muscle enzyme levels — correcting deficiency is often the simplest intervention in patients with mild, non-specific muscle symptoms) and a heating pad with vibration massage (localised heat therapy for muscle pain, stiffness, and soreness associated with myopathy or post-exercise muscle damage — providing symptomatic relief alongside medical management). These products support muscle comfort and recovery — they are not treatments for inflammatory myopathy, muscular dystrophy, or rhabdomyolysis. Inflammatory myopathy (PM/DM) requires physician-prescribed immunosuppressive therapy. Never delay or substitute medical treatment with these supportive measures.
Magnesium is the second most abundant intracellular cation in the human body (after potassium) and functions as an essential cofactor for over 300 enzymatic reactions — including multiple reactions in the glycolytic pathway that aldolase is part of. The connection between magnesium and muscle enzyme testing is clinically direct: aldolase itself requires magnesium as a cofactor for its optimal catalytic activity; phosphoglycerate mutase (another glycolytic enzyme) is magnesium-dependent; and the sodium-potassium ATPase (which maintains the electrochemical gradient necessary for muscle cell membrane integrity and normal muscle contraction) is critically magnesium-dependent. When magnesium is deficient: ATP synthesis is impaired (cells have less energy); the Na+/K+-ATPase fails to maintain normal ion gradients; the muscle cell membrane becomes more fragile and leaky; and intracellular enzymes including CK and aldolase may leak into the bloodstream at higher rates than in magnesium-sufficient individuals — potentially contributing to mildly elevated enzyme levels. Additionally, magnesium plays a critical role in muscle relaxation (counterbalancing calcium's role in muscle contraction) — magnesium deficiency causes sustained muscle contraction, cramps, and spasm. India has extremely high rates of magnesium deficiency — estimated 60–80% of Indians may be magnesium-insufficient, driven by: high reliance on processed and refined foods (which lose magnesium during processing); high phytate content in the cereal-predominant Indian diet (which binds and reduces magnesium absorption); high rates of type 2 diabetes (which causes excessive urinary magnesium loss); and widespread proton pump inhibitor use (PPIs — used for acid reflux/GERD, very common in India — reduce magnesium absorption). In patients with muscle cramps, muscle weakness, and elevated aldolase without an identifiable primary muscle disease, magnesium assessment and supplementation may be a relevant first step. Magnesium glycinate is the preferred bioavailable form — chelated to the amino acid glycine, making it significantly better absorbed than magnesium oxide (the most commonly sold form in India) and less likely to cause the gastrointestinal upset (diarrhoea) associated with magnesium sulphate, magnesium chloride, and magnesium oxide at therapeutic doses. Always check your serum magnesium level before starting supplementation. Magnesium supplementation is contraindicated in patients with chronic kidney disease (CKD) and stage 3+ renal impairment — where kidneys cannot adequately excrete excess magnesium, risking hypermagnesaemia. Discuss with your physician before starting any magnesium supplement if you have kidney disease.
Magnesium: 300+ enzymatic reactions का cofactor (including glycolysis — aldolase इसी में)। Aldolase खुद magnesium cofactor require। Na+/K+-ATPase magnesium-dependent (muscle cell membrane integrity + contraction)। Mg deficiency: ATP synthesis impaired + ATPase fail → muscle cell membrane fragile + leaky → CK + aldolase higher leak। Muscle relaxation: Mg = counterbalances Ca (contraction) → Mg deficiency = cramps, spasm। India में Mg deficiency: 60–80% insufficient (processed/refined foods, high phytate diet, T2DM urinary loss, PPIs absorption reduce)। Muscle cramps + weakness + elevated aldolase without identifiable primary disease → Mg assessment + supplementation। Magnesium glycinate: preferred bioavailable form (chelated to glycine) — magnesium oxide से significantly better absorbed, GI upset कम। Serum magnesium check before supplementation। CKD stage 3+: contraindicated — hypermagnesaemia risk। View on Amazon IndiaAffiliate link — small commission at no extra cost.
Muscle pain, stiffness, and soreness are common symptoms in the conditions that cause elevated serum aldolase — particularly in inflammatory myopathies (polymyositis, dermatomyositis), post-exercise delayed-onset muscle soreness (DOMS), statin myopathy, and the recovery phase following any acute muscle injury. The physiological basis for heat therapy in muscle pain: local heat application (thermotherapy) at 40–45°C produces multiple beneficial effects at the tissue level. Vasodilation (increased local blood flow) — heat causes arteriolar smooth muscle relaxation, increasing blood flow to the treated area by 3–4-fold. This enhanced circulation: (a) delivers more oxygen and nutrients to metabolically stressed or damaged muscle fibres; (b) removes accumulated metabolic waste products (lactic acid, potassium, bradykinin, substance P — the mediators of pain and soreness) more rapidly; and (c) in inflammatory conditions, supports the clearance of inflammatory mediators. Reduced muscle spindle activity (decreased sensitivity of the muscle stretch reflex) — heat reduces the sensitivity of the Ia afferent nerve fibres (spindle afferents) that mediate muscle tone, producing genuine muscle relaxation and reduction of protective spasm that often develops around injured or inflamed muscle tissue (the protective spasm around a painful muscle increases ischaemia and worsens pain — a positive feedback cycle broken by heat-induced relaxation). Gate control analgesia — heat activates large-diameter mechanoreceptor fibres (A-beta fibres) in the skin that "gate" (inhibit) pain transmission from injured muscle tissue through the dorsal horn of the spinal cord. This is the same mechanism used by TENS machines and massage. The vibration component of this COMFIER heating pad adds a mechanoreceptor stimulation effect on top of the thermal effect — further activating gate control analgesia and promoting local blood flow through the mechanical stimulation of vibration. For patients with myopathy awaiting specialist evaluation or on treatment, localised heat therapy to the most affected muscle groups (typically the thighs and shoulder girdle in proximal myopathy) provides meaningful symptomatic relief alongside medical management. Heat therapy is contraindicated in: acute rhabdomyolysis (where local heat increases metabolic demand in already severely damaged muscle); very acute injury within the first 24–48 hours (when ice is preferred to reduce swelling); and in areas of sensory loss (neuropathy) where temperature cannot be felt — risking burns. Always use the lowest effective heat setting. Do not fall asleep with a heating pad on. Do not apply to broken skin, rashes, or inflamed joints in active autoimmune disease flares.
Heat therapy: local heat (40–45°C) → multiple beneficial effects। Vasodilation: local blood flow 3–4× increase → O₂ + nutrients deliver। Metabolic waste remove (lactic acid, K+, bradykinin, substance P — pain mediators)। Inflammatory mediators clearance support। Muscle spindle activity reduce: Ia afferent sensitivity reduce → muscle relaxation + protective spasm break। Gate control analgesia: A-beta fibres activate → pain transmission inhibit (dorsal horn)। Vibration: mechanoreceptor stimulation → gate control analgesia enhance + local blood flow promote। Myopathy patients (awaiting specialist या on treatment): proximal muscle groups (thighs, shoulder girdle) में localised heat therapy = meaningful symptomatic relief। Contraindications: Acute rhabdomyolysis (metabolic demand increase)। Acute injury first 24–48 hours (ice preferred)। Sensory loss areas (burns risk)। Lowest effective heat setting। Sleeping with pad on: नहीं। Broken skin/rashes/active autoimmune flare joints: नहीं। View on Amazon IndiaAffiliate link — small commission at no extra cost.
Related Tests / संबंधित जांचें
These tests are commonly ordered alongside aldolase for complete muscle disease evaluation:
Aldolase के साथ ये जांचें complete muscle disease evaluation में order होती हैं:Frequently Asked Questions / अक्सर पूछे जाने वाले सवाल
An aldolase of 12.8 U/L (approximately 1.7× the upper limit of normal at 7.5 U/L) is a mild elevation that warrants attention but rarely indicates serious primary muscle disease, particularly in the absence of symptoms. The first step is to review the most common benign causes of mild aldolase elevation: Did you perform strenuous exercise (gym, running, sports) in the 5–7 days before the test? Did you receive any IM injections (gluteal, deltoid, thigh) in the past 2 weeks? Was the blood sample potentially haemolysed (improperly collected or handled)? Any recent falls, trauma, or physical injury? If any of these apply, the most appropriate action is to repeat the test after 7 days of complete rest from strenuous activity and no IM injections, with careful sample handling. If the repeat aldolase is normal — the prior elevation was a non-pathological physiological or pre-analytical cause. If the repeat aldolase remains elevated: order a simultaneous CK, ALT, AST, and LDH to contextualise the elevation. If CK is also elevated proportionally → muscle source likely, refer to rheumatologist for myopathy workup. If ALT/AST elevated but CK normal → liver source more likely, refer to gastroenterologist. If all enzymes are elevated without a clear clinical explanation → comprehensive evaluation warranted.
उत्तर: 12.8 U/L (1.7× ULN) = mild elevation, no symptoms → serious primary muscle disease less likely। First step: benign causes review। Strenuous exercise (5–7 days पहले)? IM injections (2 weeks)? Haemolysed sample? Recent trauma/fall? Any apply → 7 days rest + no IM injections + careful sampling → repeat। Repeat normal: physiological/pre-analytical। Repeat elevated: CK + ALT + AST + LDH simultaneously। CK also elevated proportionally → muscle source → rheumatologist। ALT/AST elevated + CK normal → liver source → gastroenterologist। All elevated without clear explanation → comprehensive evaluation।Both aldolase and CK (creatine kinase / CPK) are intracellular enzymes that leak into the bloodstream when muscle cells are damaged — but they are different molecules with different biochemical roles, different tissue distributions, different sensitivities, and different clinical applications. CK catalyses the phosphorylation of creatine to phosphocreatine — a rapid energy reserve in muscle cells. It has three useful isoforms in clinical practice: CK-MM (skeletal muscle), CK-MB (cardiac muscle), and CK-BB (brain). This allows CK isoform analysis to localise the source of enzyme release — a critical advantage in cardiac evaluation where CK-MB distinguishes myocardial from skeletal muscle damage. CK rises faster and higher in acute rhabdomyolysis and is the primary marker for cardiac muscle damage evaluation alongside troponin. Aldolase catalyses step 4 of glycolysis — it is a different enzyme in a different biochemical pathway. It has no routine clinical isoform analysis available in Indian labs. Aldolase is elevated in all the same conditions as CK when muscle cells are damaged, but it may be more sensitive in some specific scenarios: some inflammatory myopathy patients (10–15%) have elevated aldolase with normal or minimally elevated CK, and aldolase may be more sensitive in detecting early or low-grade myositis activity. Both are ordered together because they provide complementary information — the pattern (both elevated, only one elevated, relative degree of elevation) is more informative than either alone, and because the relative changes during treatment may differ.
उत्तर: CK (CPK): creatine phosphorylation catalyse करता है। Three isoforms: CK-MM (skeletal), CK-MB (cardiac), CK-BB (brain) — source localise possible। Cardiac evaluation में CK-MB critical। Acute rhabdomyolysis में faster + higher rise। Aldolase: glycolysis step 4 catalyse करता है। No routine clinical isoform analysis। Same conditions में elevated जब muscle cells damaged। More sensitive in: some inflammatory myopathy (10–15%: elevated aldolase + normal/minimal CK)। Early/low-grade myositis detect। Both ordered together: complementary information। Pattern (both/only one elevated, relative degree) = more informative than either alone। Treatment changes differently move हो सकते हैं।Statin-related muscle effects exist on a spectrum from benign myalgia (muscle pain without enzyme elevation) to myositis (muscle pain with enzyme elevation — your scenario) to severe rhabdomyolysis (massive muscle breakdown with very high enzymes and risk of kidney failure). An elevated aldolase in a patient on atorvastatin (or any statin) should prompt measurement of CK — because CK is the primary marker used in clinical guidelines for assessing statin myopathy severity. The clinical guidelines for statin myopathy management (Endocrine Society, ACC/AHA): If muscle symptoms are present and CK is above 4× the upper limit of normal: consider reducing the statin dose or switching to a lower-intensity statin. If CK is above 10× ULN with muscle symptoms: discontinue the statin immediately. If CK is above 10,000 U/L (rhabdomyolysis level): admit to hospital for IV fluid therapy and kidney function monitoring. What should you do: contact your cardiologist or physician immediately — do not stop the statin without medical guidance (as statins provide significant cardiovascular protection and the decision to stop requires risk-benefit assessment). Bring both the aldolase and CK results to the appointment. Other important considerations: statin myopathy is more likely with high-intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg), with interacting medications (amiodarone, diltiazem, some antibiotics, antifungals — which increase statin blood levels through CYP450 interactions), and in patients with hypothyroidism, vitamin D deficiency, or renal impairment.
उत्तर: Statin muscle effects spectrum: myalgia (pain, no enzyme elevation) → myositis (pain + enzyme elevation — your scenario) → rhabdomyolysis (massive breakdown + AKI risk)। Atorvastatin + elevated aldolase → CK measure immediately (primary guideline marker)। Guidelines: CK >4× ULN + symptoms: dose reduce या lower-intensity statin switch। CK >10× ULN + symptoms: immediately discontinue। CK >10,000 (rhabdomyolysis): hospital admission, IV fluids, kidney function monitor। Do: cardiologist/physician contact immediately — statin without medical guidance stop नहीं (CV protection significant, risk-benefit assessment)। Aldolase + CK results bring। Other considerations: high-intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) में more likely। Interacting medications (amiodarone, diltiazem, antibiotics, antifungals — CYP450)। Hypothyroidism, Vitamin D deficiency, renal impairment।Very high CK (often 50–200× the upper limit of normal) and elevated aldolase in a boy with muscle weakness and difficulty walking or running in the first 2–5 years of life is the classic presentation of Duchenne Muscular Dystrophy (DMD) — the most common and most severe form of muscular dystrophy. The next steps after finding very high muscle enzymes in a child with suspected muscular dystrophy: First, urgent referral to a paediatric neurologist or paediatric neuromuscular specialist. Second, genetic testing — the definitive diagnosis of DMD and Becker MD requires molecular genetic testing of the dystrophin gene (the DMD gene on the X chromosome): MLPA (Multiplex Ligation-dependent Probe Amplification) is the first-line test for detecting the large deletions and duplications that account for approximately 65–70% of DMD cases; DNA sequencing for point mutations (approximately 25–30% of cases); RNA analysis in rare cases. Genetic testing is available at medical genetics departments at major Indian hospitals (AIIMS Delhi, Bombay, Madras, CMC Vellore, NIMHANS, and private genetics labs). Third, cardiac evaluation (echocardiogram) — DMD invariably involves cardiac muscle (cardiomyopathy develops in virtually all boys with DMD by adolescence). Fourth, pulmonary function testing — respiratory muscle involvement causes progressive respiratory insufficiency. Fifth, family genetic counselling — DMD is X-linked, meaning female carriers can pass it to sons; sisters and the mother should be offered carrier testing.
उत्तर: Very high CK (50–200× ULN) + elevated aldolase + boy + muscle weakness (first 2–5 years) = Duchenne MD (DMD) classic presentation। Next steps: 1. Urgent paediatric neurologist/neuromuscular specialist referral। 2. Genetic testing: MLPA (first-line, 65–70% DMD — large deletions/duplications detect)। DNA sequencing (25–30% point mutations)। RNA analysis (rare cases)। Available: AIIMS Delhi/Bombay/Madras, CMC Vellore, NIMHANS, private genetics labs। 3. Cardiac evaluation (echocardiogram — cardiomyopathy virtually all DMD boys by adolescence)। 4. Pulmonary function testing। 5. Family genetic counselling (X-linked — female carriers; sisters + mother carrier testing offer)।Yes — elevated serum aldolase does not exclusively indicate muscle disease. Liver cells (hepatocytes) contain significant amounts of Aldolase B — and acute liver damage from any cause (viral hepatitis A, B, C, E; alcoholic hepatitis; drug-induced liver injury including paracetamol toxicity; autoimmune hepatitis; ischaemic hepatitis) releases hepatic aldolase into the bloodstream, elevating serum total aldolase. In practice, the pattern of other enzyme elevations distinguishes the source: In muscle disease: CK is typically markedly elevated (proportionally greater than ALT/AST elevation); aldolase elevation parallels CK. ALT and AST may be mildly elevated from muscle cell damage (both enzymes are present in muscle) but are not the dominant enzymes elevated. In liver disease: ALT (SGPT) and AST (SGOT) are the dominant enzyme elevations (ALT typically greater than AST in hepatitis); CK is normal or only mildly elevated; aldolase may be elevated but is not the primary marker used. ALP and bilirubin help further characterise liver disease. A simple way to suspect liver-source aldolase elevation: if the ALT elevation is 3–5× greater proportionally than any CK elevation, the liver is the more likely source. Muscle MRI can also help distinguish — active myopathy shows characteristic signal changes in affected muscles that are absent in liver disease.
उत्तर: हाँ — elevated aldolase exclusively muscle disease नहीं। Hepatocytes में significant Aldolase B। Acute liver damage (viral hepatitis A/B/C/E, alcoholic hepatitis, drug-induced, autoimmune, ischaemic) → hepatic aldolase bloodstream में → serum total aldolase elevated। Pattern distinguishes source: Muscle disease: CK markedly elevated (ALT/AST से proportionally greater)। ALT + AST mildly elevated (muscle में present)। Liver disease: ALT (SGPT) + AST (SGOT) dominant elevations (hepatitis में ALT > AST typically)। CK normal/mildly elevated। Aldolase elevated but not primary marker। ALP + bilirubin liver disease characterise। Simple distinction: ALT elevation 3–5× greater proportionally than CK → liver more likely source। Muscle MRI: active myopathy → characteristic signal changes (liver disease में absent)।- ACR (American College of Rheumatology) — Inflammatory Myopathy Guidelines: ACR — Classification Criteria and Management of Inflammatory Myopathy
- TREAT-NMD (International Neuromuscular Disease Network): TREAT-NMD — Muscular Dystrophy Diagnosis and Care Standards
- MedlinePlus (NIH) — Aldolase Test: Aldolase Test — Patient Information
⚠️ Medical Disclaimer / चिकित्सा अस्वीकरण
This article is for educational purposes only. Aldolase results must be interpreted by a qualified rheumatologist, neurologist, or physician alongside clinical symptoms (pattern and severity of muscle weakness, skin changes), complete muscle enzyme panel (CK, LDH, ALT, AST), inflammatory markers, myositis-specific antibody testing, electromyography (EMG), nerve conduction studies, muscle MRI, and muscle biopsy where indicated. An elevated aldolase does not by itself diagnose inflammatory myopathy, muscular dystrophy, or any specific muscle disease — it requires comprehensive clinical and diagnostic evaluation. Never start or stop immunosuppressive medications or statins based on enzyme levels alone without physician guidance. Rhabdomyolysis (very high CK and aldolase with dark urine) is a medical emergency requiring urgent hospital admission.
यह लेख केवल शैक्षिक उद्देश्यों के लिए है। Aldolase results को rheumatologist/neurologist से symptoms + muscle enzyme panel + myositis antibody panel + EMG + NCS + muscle MRI + biopsy के साथ interpret। Elevated aldolase alone = no specific disease diagnose। Comprehensive evaluation required। Immunosuppressives या statins enzyme levels alone पर start/stop नहीं। Rhabdomyolysis (very high CK + aldolase + dark urine) = MEDICAL EMERGENCY — urgent hospital admission।
Comments
Post a Comment